Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug cocktails target deadly ovarian cancer

NCT ID NCT07059845

Recruiting now Disease control Sponsor: AbbVie Source: ClinicalTrials.gov ↗

Summary

This study is testing different combinations of an experimental drug called mirvetuximab soravtansine with two other cancer drugs (carboplatin or bevacizumab) for ovarian cancer. It aims to find the safest and most effective doses for patients whose tumors have a specific marker. About 320 participants worldwide will receive these treatments through IV infusions and be closely monitored for side effects and tumor response.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Austin Hospital /ID# 276534

    RECRUITING

    Melbourne, Victoria, 3084, Australia

  • Burnside War Memorial Hospital /ID# 277602

    RECRUITING

    Adelaide, South Australia, 5065, Australia

  • Icon Cancer Centre Hobart /ID# 277688

    RECRUITING

    Hobart, Tasmania, 7000, Australia

  • Icon Cancer Centre Wesley /ID# 277199

    RECRUITING

    Auchenflower, Queensland, 4066, Australia

  • Korea University Guro Hospital /ID# 276194

    RECRUITING

    Seoul, Seoul Teugbyeolsi, 08308, South Korea

  • Monash Health - Monash Medical Centre /ID# 276984

    RECRUITING

    Clayton, Victoria, 3168, Australia

  • Samsung Medical Center /ID# 276261

    RECRUITING

    Seoul, Seoul Teugbyeolsi, 06351, South Korea

  • Seoul National University Hospital /ID# 276182

    RECRUITING

    Seoul, Seoul Teugbyeolsi, 03080, South Korea

  • St. George Private Hospital /ID# 276570

    RECRUITING

    Kogarah, New South Wales, 2217, Australia

  • Yonsei University Health System Severance Hospital /ID# 276266

    RECRUITING

    Seoul, Seoul Teugbyeolsi, 03722, South Korea

Conditions

Explore the condition pages connected to this study.

OVARIAN CANCER